Particles in Biologics: Advanced Analytics and Tech Transfer

About this episode

This episode discusses the importance of analyzing particle populations in biologics to improve formulation stability and process development.

For many teams, particles and aggregates are treated as a late-stage compliance headache or a sudden fire drill during manufacturing. But what if we looked closer? Particle populations can actually reveal deep insights about your formulation stability, process robustness, and potential technology transfer risks long before you reach commercial scale. In this episode of Life Science Solutions, host Chris Adkins sits down with Dr. Tim Menzen, Chief Technology Officer at Coriolis Pharma, a science-driven CRO specializing in formulation development and advanced analytics for biopharmaceuticals. With a PhD focused on the thermal unfolding and aggregation of monoclonal antibodies, Tim brings a wealth of expertise to the evolving landscape of biologic particles. If your organization is looking to modernize how it approaches formulation and process development, this conversation is packed with cutting-edge insights. Topics Include: The Evolution of Antibodies: How improved molecular engineering has shifted the industry away from from-scratch formulation and toward streamlined "formulability assessments". Tech Transfer Risks: Why pumps are famously considered "particle generating…

People in this episode

Host: Chris Adkins

Guest: Dr. Tim Menzen

Topics covered

• biologics
• advanced analytics
• tech transfer
• formulation stability
• process robustness
• particle characterization

Keywords

• particles
• aggregates
• formulation development
• monoclonal antibodies
• tech transfer risks
• submicron particles
• orthogonal analytics

Mentioned in this episode

Organizations: Coriolis Pharma